The effects on lipid serum levels of a 2-year adjuvant treatment with exemestane after tamoxifen in postmenopausal women with early breast cancer
| Autor: | Ranuccio Nuti, K. Del Santo, Carla Caffarelli, C. Pieropan, M. Montomoli, Roberto Petrioli, Stefano Gonnelli, A. Cadirni, Andrea Montagnani, Maria Stella Campagna |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Oncology
medicine.medical_specialty Antineoplastic Agents Hormonal medicine.drug_class medicine.medical_treatment Antineoplastic Agents Breast Neoplasms Cohort Studies chemistry.chemical_compound Breast cancer Estrogen Receptor Modulators Exemestane Internal medicine Internal Medicine medicine Adjuvant therapy Humans Single-Blind Method skin and connective tissue diseases Triglycerides Aged Aromatase inhibitor Postmenopausal women medicine.diagnostic_test Aromatase Inhibitors business.industry Cholesterol HDL Cholesterol LDL Middle Aged medicine.disease Lipids Androstadienes Postmenopause Tamoxifen Treatment Outcome chemistry Chemotherapy Adjuvant Body Composition Female Lipid profile business Adjuvant Biomarkers medicine.drug |
| Zdroj: | European Journal of Internal Medicine. 19:592-597 |
| ISSN: | 0953-6205 |
| DOI: | 10.1016/j.ejim.2007.05.016 |
| Popis: | The third-generation aromatase inhibitor exemestane represents a new development in the treatment of estrogen-positive breast cancer. The aim of this study was to evaluate the effects on lipid profile and body composition of the shift from tamoxifen to exemestane.After 2-3 years of tamoxifen adjuvant treatment, 68 postmenopausal women were randomly assigned to either continue tamoxifen 20 mg/day (n = 35) or to switch to exemestane 25 mg/day (n = 33).No significant changes in lipid profile were found in patients continuing on tamoxifen. In the exemestane group, serum HDL-cholesterol (HDL-C) and triglycerides (TG) decreased significantly (p0.01) and serum LDL-cholesterol (LDL-C) increased significantly (p0.05) with respect to baseline. The difference between the two groups was significant. Moreover, in the exemestane group, fat mass (FM) and fat-free mass (FFM) showed an opposite trend, which determined a progressive and significant increase in the FFM/FM ratio.This study shows that the choice of first-line treatment or adjuvant therapy for breast cancer should also take the individual lipid and body composition profile into account. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect